leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...5657585960616263646566...235236»
  • ||||||||||  Journal:  Oral Chemotherapeutic Ingestions Reported to a Poison Control Center Treated in a Health Care Facility. (Pubmed Central) -  Mar 13, 2023   
    Although methotrexate is the most common oral chemotherapeutic agent involved in overdoses reported to the California Poison Control System, there are many other oral chemotherapeutics from various drug classes, which can lead to toxicity. Although deaths are rare, further studies are needed to determine if particular drugs or drug classes warrant more scrutiny.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Nivolumab-induced Central Nervous System (CNS) Vasculitis Brought on by a Steroid Taper (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_3987;    
    Generally, both intra- and extracranial vasculitides are treated with steroids Objective To illustrate a case of nivolumab-induced CNS vasculitis that developed while tapering steroids and was successfully treated expectantly without immunosuppression Design/Methods N/A Results A 75 year-old male received two months of concurrent chemoradiation with weekly carboplatin/paclitaxel for esophageal adenocarcinoma...Work-up suggested ICI-associated pneumonitis, and he was started on 50 mg prednisone, with weekly taper...Additionally, this patient underwent biopsy with concern for metastasis or abscess, but ultimately did not necessitate treatment for vasculitis. This raises the possibility that active surveillance is a reasonable management strategy in cases of self-resolving ICI-associated CNS vasculitis
  • ||||||||||  5-fluorouracil / Generic mfg.
    Osmotic Demyelinating Syndrome Secondary to Breast Cancer Chemotherapy: a Case Report (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_3402;    
    In another study published by Cortes and colleagues, the development of osmotic demyelinating syndrome when using a combination of trastuzumab and pertuzumab for breast cancer was reported as a rare finding (one case of twenty-nine patients). To our knowledge, this is one of the first cases describing an ODS following therapy with pertuzumab, trastuzumab, and docetaxel.
  • ||||||||||  dexamethasone / Generic mfg., leucovorin calcium / Generic mfg.
    Transmission of Behavioral Deficits in Rats Exposed to Folate Receptor Alpha Antibody In Utero. (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_1545;    
    We hypothesize that treatment of the directly exposed generation with folinic acid prior to mating may prevent transmission of behavioral deficits to a subsequent generation by altering the epigenome. This may be a strategy to decrease the risk in families with a history of ASD.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (clinicaltrials.gov) -  Mar 10, 2023   
    P2,  N=124, Active, not recruiting, 
    Trial primary completion date: Jan 2023 --> Jun 2023 Recruiting --> Active, not recruiting | N=196 --> 124 | Trial completion date: Sep 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Apr 2023
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Preclinical, Journal:  Matairesinol Nanoparticles Restore Chemosensitivity and Suppress Colorectal Cancer Progression in Preclinical Models: Role of Lipid Metabolism Reprogramming. (Pubmed Central) -  Mar 9, 2023   
    Finally, matairesinol-loaded liposomes significantly promoted the enhanced antitumor activity of 5-Fu/leucovorin combined with oxaliplatin (FOLFOX) in CDX and PDX mouse models by restoring chemosensitivity to the FOLFOX regimen. Collectively our findings highlight matairesinol-mediated lipid metabolism reprogramming as a novel druggable strategy to restore CRC chemosensitivity, and this nanoenabled approach for matairesinol will improve the chemotherapeutic efficacy with good biosafety.
  • ||||||||||  5-fluorouracil / Generic mfg.
    P2 data, Clinical Trial,Phase II, Journal, Metastases:  Long-term results of a phase 2 study of neoadjuvant chemotherapy with molecularly targeted agents for locally advanced rectal cancer. (Pubmed Central) -  Mar 9, 2023   
    Collectively our findings highlight matairesinol-mediated lipid metabolism reprogramming as a novel druggable strategy to restore CRC chemosensitivity, and this nanoenabled approach for matairesinol will improve the chemotherapeutic efficacy with good biosafety. The use of molecularly targeted agents in the neoadjuvant setting for locally advanced rectal cancer has an acceptable prognosis.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Clinical, Retrospective data, Journal, Metastases:  Chemotherapy in advanced pancreatic adenosquamous carcinoma: a retrospective multicenter AGEO study. (Pubmed Central) -  Mar 9, 2023   
    The first-line treatment was chemotherapy for 79 patients (84.0%) (37 FOLFIRINOX (FX), 7 Gemcitabine-nab paclitaxel (GN) and 35 for all other regimen) or best supportive care (BSC) alone for 15 patients (16.0%)...This large study evaluating first-line treatment regimens in advanced PASC suggests that modern regimens as FX or GN may be preferable to all other chemotherapy regimens. These results deserve confirmation in prospective studies.
  • ||||||||||  monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
    Enrollment closed, Trial completion date, IO biomarker, Metastases:  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) -  Mar 9, 2023   
    P1/2,  N=383, Active, not recruiting, 
    These results deserve confirmation in prospective studies. Completed --> Active, not recruiting | Trial completion date: Oct 2021 --> Jun 2023
  • ||||||||||  Tibsovo (ivosidenib) / Servier
    Cost () -  Mar 9, 2023 - Abstract #ISPOR2023ISPOR_549;    
    However, the Taiwan National Health Insurance (NHI) only reimburses fluorouracil/leucovorin (5-FU/LV) for these patients. In our study, ivosidenib was not cost-effective compared with mFOLFOX or 5-FU/LV in IDH1-mutant ICC patients from the Taiwan NHI
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Journal:  The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. (Pubmed Central) -  Mar 7, 2023   
    Randomized ongoing trials are eagerly awaited with more active combined regimens including modified FOLFIRINOX. The results suggest that the recommendation of a lower starting dose of nal-IRI for patients with UGT1A1?28 homozygosity should be extended to include patients with UGT1A1?6 homozygosity/compound heterozygosity.
  • ||||||||||  Journal:  Selection Bias Due to Delayed Comprehensive Genomic Profiling in Japan. (Pubmed Central) -  Mar 7, 2023   
    There was no difference in survival between FOLFIRINOX or Gemcitabine with nab-paclitaxel-treated groups as first-line chemotherapy for pancreatic cancer. Adjusting for length bias is an essential part of utilizing real-world clinicogenomic data.
  • ||||||||||  Journal:  ASO Visual Abstract: CA19-9 (Pubmed Central) -  Mar 7, 2023   
    Trial completion date: Jan 2023 --> Jan 2024 No abstract available
  • ||||||||||  izalontamab (SI-B001) / Biokin Pharma
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases:  SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies (clinicaltrials.gov) -  Mar 6, 2023   
    P2,  N=7, Terminated, 
    No abstract available N=120 --> 7 | Trial completion date: Sep 2023 --> Jun 2022 | Recruiting --> Terminated | Trial primary completion date: Sep 2023 --> Jun 2022; Company research strategy adjustment
  • ||||||||||  Vyloy (zolbetuximab-clzb) / Astellas
    Biomarker, Enrollment closed, Monotherapy:  ILUSTRO: A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (clinicaltrials.gov) -  Mar 6, 2023   
    P2,  N=116, Active, not recruiting, 
    N=120 --> 7 | Trial completion date: Sep 2023 --> Jun 2022 | Recruiting --> Terminated | Trial primary completion date: Sep 2023 --> Jun 2022; Company research strategy adjustment Recruiting --> Active, not recruiting
  • ||||||||||  Review, Journal:  A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer. (Pubmed Central) -  Mar 4, 2023   
    Randomized controlled trials assessing the value of neoadjuvant FOLFIRINOX in clearly resectable pancreatic cancer, which are expected to provide more conclusive recommendations, are still ongoing. This review outlines the rationale, considerations, and current level of evidence for the use of neoadjuvant therapy in patients with clearly resectable pancreatic cancer.